… oxypurinol, allopurinol, or allopurinol riboside plasma concentrations. Thus, our results do not
support a major role of ABCG2 in the pharmacokinetics of allopurinol … ABCG2 in oxypurinol …

… for influencing the clinical pharmacokinetics and metabolism of drugs [60]. Although this does
not invalidate our results, it is possible that allopurinol and metabolite concentrations could …

… ) method has been developed for the simultaneous determination of allopurinol (AP), a
xanthine oxidase inhibitor and its active metabolite oxypurinol (OP) in human plasma and AP in …

… the comparative effectiveness of allopurinol vs. febuxostat for … patients newly treated with
allopurinol or febuxostat (baseline … renal disease with allopurinol use and allopurinol dose vs. …

… Oxypurinol is the active metabolite of allopurinol, a drug … % reduction in renal clearance of
oxypurinol has been reported [17]… directly due to a pharmacokinetic interaction with oxypurinol. …

… Allopurinol in plasma was stable at benchtop for 24 h, in … Allopurinol stock standard solutions
were stable for 140 days … samples in pharmacokinetic study of an allopurinol formulation. …

… In this in-depth review, we discuss clinical pharmacokinetic and pharmacodynamic
considerations for most common IBD drug classes that can be of help in making this choice. …

… ) inhibitor allopurinol, has been the cornerstone of the clinical … Allopurinol and its active
metabolite oxypurinol showed … and in small-scale human clinical trials. Although some of the …

… The primary active metabolite of allopurinol is oxypurinol, which is filtered and partially
reabsorbed in the kidneys. Oxypurinol has the same mechanism of action of allopurinol, but a …

… Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol,
is the … Our results demonstrate that oxypurinol and urate are removed by peritoneal dialysis, …